Articles
Patient perspectives: Amy Tenderich

Patient perspectives: Amy Tenderich

As our Patient perspective series continues, we speak with Amy Tenderich on her experience as a diabetes patient and advocate and her ideas on where devices for diabetes should be heading. Back in 2003 at the time of Amy’s diagnosis there was little in the way of online patient resources or online areas where patients …

Articles
Crikey, what a headache – pharmaceutical litigation, compensation and causation in Australia

Crikey, what a headache – pharmaceutical litigation, compens...

Mabel Tsui discusses the progress to date of the Merck Sharp Dohme (Australia) Pty Ltd v Peterson case in Australia to date and how it highlights the need for tort law reform in Australia when it comes to pharmaceutical product litigation. In October 2011, the Full Court of the Federal Court of Australia handed down their judgment in the case...

Articles
Patent filings and maintenance cost money

Patent filings and maintenance cost money

Taffy Williams gives us a lesson on the filing and maintenance of patents. Name brand pharmaceuticals are created and proprietary to the inventing company for the life time of any patents covering the products. Generic drugs began to...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. UK budget includes £1bn biopharma investment package
  2. HHS doubles down on controversial peptides plan
  3. Lilly's triple G overpowers Ozempic in diabetes trial
  4. UK puts £100m into "world-first" AI biosecurity facility
  5. US gives $99m for Ebola jab project, as cases spread in Africa

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more